Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1677
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2495
    -0.0016 (-0.13%)
     

  • Bitcoin GBP

    51,140.83
    -646.88 (-1.25%)
     

  • CMC Crypto 200

    1,332.45
    -64.08 (-4.59%)
     

  • S&P 500

    5,110.36
    +61.94 (+1.23%)
     

  • DOW

    38,295.44
    +209.64 (+0.55%)
     

  • CRUDE OIL

    83.74
    +0.17 (+0.20%)
     

  • GOLD FUTURES

    2,349.00
    +6.50 (+0.28%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Europe gives green light to AbbVie hepatitis C drugs, others

Reuters - UK Focus

(Adds further recommendations, additional indication for Otezla)

LONDON, Nov 21 (Reuters) - European regulators recommended approval for two drugs made by AbbVie (Xetra: 4AB.DE - news) to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe.

Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday.

The all-oral regimens for patients infected with the virus avoided the need for interferons, which are delivered by injection, the agency said.

ADVERTISEMENT

Sanofi (NasdaqGM: GCVRZ - news) 's eliglustat, a medicine marketed as Cerdelga to treat the rare genetic disorder type 1 Gaucher disease that was approved in the United States in August, was also given the green light in Europe.

The European Medicines Agency said patients could take the drug orally, making it a convenient alternative to other treatments delivered by intravenous injection.

Boehringer Ingelheim's lung-disorder drug nintedanib was also recommended for approval on Friday.

The regulator gave the nod to Novartis (Xetra: 904278 - news) ' anti-inflammation drug secukinumab, or Cosentyx, to treat the most common form of the painful, unsightly skin condition plaque-psoriasis.

Celgene's apremilast, known as Otezla, was recommended to treat both psoriatic arthritis, which is a type of arthritis associated with the skin disease psoriasis that cause joint pain, stiffness and swelling, and for moderate to severe cases of psoriasis itself. The drug was approved in the United States in March.

Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use are usually endorsed by the European Commission within a couple of months. (Reporting by Paul Sandle; editing by Sarah Young and Jane Merriman)